Novartis has released new data showing that its drug Gilenya benefited patients by improving all four key measures of multiple sclerosis (MS). Gilenya (fingolimod) is the first once-daily oral ...

It will not be the most expensive but it will not be the cheapest – a very effective drug at the same list price as Gilenya.” When NICE assessed Gilenya back in 2012, it said the drug costs ...

A US court has ordered generic drug makers to stop selling a copy of Gilenya in US. The annual sales of Gilenya, a drug used to treat multiple sclerosis, was about $3.3 billion in 2018.